Five medical provide insights around breakthrough treatment strategies in relapsed/recurrent DLBCL.
EP. 1: Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning
Medical experts highlight second-line options for treating patients with DLBCL.
EP. 2: Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer
First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups
IBI343 Is Safe, Generates Preliminary Efficacy in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma